Literature DB >> 25209833

Total polysaccharide of Yupingfeng protects against bleomycin-induced pulmonary fibrosis via inhibiting transforming growth factor-β1-mediated type I collagen abnormal deposition in rats.

Liang Xu1, Liu-cheng Li, Ping Zhao, Lian-wen Qi, Ping Li, Jian Gao, Guang-he Fei.   

Abstract

OBJECTIVE: This study was to explore the antifibrotic effect and the possible mechanism of total polysaccharides of Yupingfeng (YPF-P) on bleomycin (BLM)-induced pulmonary fibrosis in rats.
METHODS: Pulmonary fibrosis was induced in Sprague-Dawley rats by BLM (5 mg/kg), killed 14 and 28 days after BLM administration by abdominal aorta exsanguination and removed the lungs. Lung coefficient was counted at the same time. Besides, H&E and Masson's trichrome staining for histopathological changes of lung tissues were observed. Additionally, western blotting and immunohistochemical staining techniques were used to detect expression of transforming growth factor-β1 (TGF-β1), type I collagen (Col-I) and α-smooth muscle actin (α-SMA). Finally, the levels of Col-I and hydroxyproline (HYP) in lung tissues were also utilized. KEY
FINDINGS: YPF-P alleviated the increase of lung coefficient induced by BLM instillation in pulmonary fibrosis rat, pathologic changes and collagen distribution were obviously ameliorated, while the increase of α-SMA-positive cells and TGF-β1 expression was prevented after YPF-P treatment. Moreover, the contents of HYP and Col-I were decreased in YPF-P group.
CONCLUSIONS: YPF-P had antifibrotic effect in experiment, which may reduce the synthesis and promote the deposition of Col-I via suppressing the increase of TGF-β1-mediated activation of myofibroblasts.
© 2014 Royal Pharmaceutical Society.

Entities:  

Keywords:  Yupingfeng polysaccharide; pulmonary fibrosis; transforming growth factor-β1; type I collagen; α-smooth muscle actin

Mesh:

Substances:

Year:  2014        PMID: 25209833     DOI: 10.1111/jphp.12308

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Nrf2 inhibits epithelial-mesenchymal transition by suppressing snail expression during pulmonary fibrosis.

Authors:  Wencheng Zhou; Xiaoting Mo; Wenhui Cui; Zhihui Zhang; Delin Li; Liucheng Li; Liang Xu; Hongwei Yao; Jian Gao
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

2.  Telmisartan improves vascular remodeling through ameliorating prooxidant and profibrotic mechanisms in hypertension via the involvement of transforming growth factor-β1.

Authors:  Peijin Shang; Tianlong Liu; Wenxing Liu; Yuwen Li; Fang Dou; Yikai Zhang; Lijuan Sun; Tiejun Zhang; Zhihui Zhu; Fei Mu; Yi Ding; Aidong Wen
Journal:  Mol Med Rep       Date:  2017-08-04       Impact factor: 2.952

3.  Activation of Wnt/β-catenin signalling is required for TGF-β/Smad2/3 signalling during myofibroblast proliferation.

Authors:  Liang Xu; Wen-Hui Cui; Wen-Cheng Zhou; De-Lin Li; Liu-Cheng Li; Ping Zhao; Xiao-Ting Mo; Zhihui Zhang; Jian Gao
Journal:  J Cell Mol Med       Date:  2017-02-28       Impact factor: 5.310

4.  Nrf2 antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis.

Authors:  Zhihui Zhang; Jiao Qu; Cheng Zheng; Panpan Zhang; Wencheng Zhou; Wenhui Cui; Xiaoting Mo; Liucheng Li; Liang Xu; Jian Gao
Journal:  Cell Death Dis       Date:  2018-01-23       Impact factor: 8.469

Review 5.  A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV.

Authors:  Rui-Rong Chen; Ya-Jun Li; Jun-Jia Chen; Chuan-Li Lu
Journal:  Carbohydr Polym       Date:  2020-07-07       Impact factor: 9.381

6.  Gastric Acid and Pepsin Work Together in Simulated Gastric Acid Inhalation Leading to Pulmonary Fibrosis in Rats.

Authors:  Shi Chen; HongYu Chen; Yue Cheng; Yu Wei; XianMei Zhou; Tian Li; JiPing Zhu; Qian Wang
Journal:  Med Sci Monit       Date:  2019-08-16

Review 7.  Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.

Authors:  Liu-Cheng Li; Lian-Di Kan
Journal:  J Ethnopharmacol       Date:  2016-12-28       Impact factor: 4.360

Review 8.  A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone.

Authors:  Ruizhe Yu; Shihan Zhang; Dejian Zhao; Zhanpeng Yuan
Journal:  Expert Rev Mol Med       Date:  2022-01-06       Impact factor: 5.600

Review 9.  Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis.

Authors:  Josep Mercader-Barceló; Joan Truyols-Vives; Carlos Río; Nora López-Safont; Ernest Sala-Llinàs; Alice Chaplin
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.